Glycosylation of monoclonal antibody products: Current status and future prospects
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Protein based therapeutics have started to dominate the pharmaceutical landscape primarily due to the high efficacy that they have demonstrated against complex diseases. Despite the significant success, issues with regards to safety, efficacy and quality of biotherapeutics have been a point of considerable debate and concern among the various stakeholders. The correlation between the glycoform profile and the safety and efficacy of a drug, in particular, has garnered significant attention of researchers worldwide. An escalated emphasis is presently given to develop an understanding of how the various process parameters as well molecular biology considerations contribute to glycan heterogeneity. This paper aims to review the major developments that have occurred in this area over the last decade. The impact of the various process parameters on glycan expression, methods for obtaining a pre‐determined glycan levels/profiles of a protein therapeutic and developments in the area of real‐time glycan monitoring and control are discussed. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:1091–1102, 2016
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“expressed in Lec13 mutant have exhibited a 50-fold improvement in binding to FccRIIIa and a 100-fold increase in the ADCC activity.(14) Absence of core fucose leads to”
BackgroundAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“Heterogeneity of antibody glycoforms imposes a significant challenge to the biopharmaceutical industry.(3) It is well accepted that conformation of an immunoglobulin (Ig) molecule is not just determined by its polypeptide sequence but also by multiple interactions that occur between polypeptide structure and carbohydr…”
BackgroundKim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801 · cited 2×
“The CHO cell line differs from the human cells with respect to the linkage between sialic acid and galactose as CHO cells lack the a2,6 sialyltransferase enzyme and generate only a-2,3-linked sialylated glycans whereas the humans cells exhibit both a2,3- & a-2,6-linked sialylated glycans with a preference for the latt…”
BackgroundFerrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 2×
“Another prominent difference is the absence of functional GnTIII enzyme which prevents the addition of bisecting GlcNAc residue.(18,33) Microheterogeneities introduced by the NS0 cells include addition of a-1,3-galactose epitope and Figure 3.”
BackgroundCell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467
Cited by
Capillary Electrophoresis Separations of Glycans
Lu, G., Crihfield, C. L., Gattu, S., Veltri, L. M., & Holland, L. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00669 · Cited by 174
Belov, A. M., Zang, L., Sebastiano, R., Santos, M. R., Bush, D. R., Karger, B. L., & Ivanov, A. R. (2018) · ELECTROPHORESIS · doi:10.1002/elps.201800067 · Cited by 88
Wang, C., Wang, J., Chen, M., Fan, L., Zhao, L., & Tan, W.-S. (2018) · Biotechnology Letters · doi:10.1007/s10529-018-2586-4 · Cited by 11
Bravo-Venegas, J., Rodriguez-Siza, J., Vergara, M., Torres, M., Dickson, A., Toledo, J. R., Molina, M. C., Hermoso, M. A., Berríos, J., & Altamirano, C. (2026) · mAbs · doi:10.1080/19420862.2026.2643039 · Cited by 6
“9,10 Factors such as the choice of the host cell line, cell culture conditions, and nutrient supply can significantly impact the glycosylation patterns.”
Metadata
- Authors
- Batra, J., & Rathore, A. S.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2016-09
- Volume
- 32
- Issue
- 5
- Pages
- 1091-1102
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2526872992
- Cited by
- 63
- References
- 23
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycosylation of monoclonal antibody products: Current status and future prospects. https://app.cochat.ai/papers/10.1002/btpr.2366
- The paper
- Batra, J., & Rathore, A. S. (2016). Glycosylation of monoclonal antibody products: Current status and future prospects. Biotechnology Progress. https://doi.org/10.1002/btpr.2366
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.